OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Takashi Niizeki, Takayuki Tokunaga, Yuko Takami, et al.
Targeted Oncology (2022) Vol. 17, Iss. 6, pp. 643-653
Open Access | Times Cited: 31
Takashi Niizeki, Takayuki Tokunaga, Yuko Takami, et al.
Targeted Oncology (2022) Vol. 17, Iss. 6, pp. 643-653
Open Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
Anand V. Kulkarni, Harsh Vardhan Tevethia, Karan Kumar, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102179-102179
Open Access | Times Cited: 26
The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, et al.
Cancer Medicine (2023) Vol. 12, Iss. 11, pp. 12325-12335
Open Access | Times Cited: 19
Shigeo Shimose, Hideki Iwamoto, Tomotake Shirono, et al.
Cancer Medicine (2023) Vol. 12, Iss. 11, pp. 12325-12335
Open Access | Times Cited: 19
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
Najib Ben Khaled, Marie Møller, Leonie Jochheim, et al.
JHEP Reports (2024) Vol. 6, Iss. 6, pp. 101065-101065
Open Access | Times Cited: 7
Najib Ben Khaled, Marie Møller, Leonie Jochheim, et al.
JHEP Reports (2024) Vol. 6, Iss. 6, pp. 101065-101065
Open Access | Times Cited: 7
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 242-251
Open Access | Times Cited: 12
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 242-251
Open Access | Times Cited: 12
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Kaoru Tsuchiya, Yu‐Yun Shao, et al.
Liver Cancer (2023) Vol. 13, Iss. 4, pp. 401-412
Open Access | Times Cited: 11
Masatoshi Kudo, Kaoru Tsuchiya, Yu‐Yun Shao, et al.
Liver Cancer (2023) Vol. 13, Iss. 4, pp. 401-412
Open Access | Times Cited: 11
What Is the Role of Minimally Invasive Liver Surgery in Treating Patients with Hepatocellular Carcinoma on Cirrhosis?
Alessandro Vitale, Roberta Angelico, Bruno Sensi, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 966-966
Open Access | Times Cited: 4
Alessandro Vitale, Roberta Angelico, Bruno Sensi, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 966-966
Open Access | Times Cited: 4
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: systematic review and metanalysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
JHEP Reports (2025), pp. 101431-101431
Open Access
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
JHEP Reports (2025), pp. 101431-101431
Open Access
Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Tao Meng, Jing Han, Juanyi Shi, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1069-1083
Open Access | Times Cited: 10
Tao Meng, Jing Han, Juanyi Shi, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1069-1083
Open Access | Times Cited: 10
Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis
Jinpeng Lu, Xinyi Lin, H Teng, et al.
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 6, pp. 643-651
Closed Access | Times Cited: 3
Jinpeng Lu, Xinyi Lin, H Teng, et al.
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 6, pp. 643-651
Closed Access | Times Cited: 3
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
T. de Castro, Sabrina Welland, Leonie Jochheim, et al.
Hepatology Communications (2024) Vol. 8, Iss. 11
Open Access | Times Cited: 3
T. de Castro, Sabrina Welland, Leonie Jochheim, et al.
Hepatology Communications (2024) Vol. 8, Iss. 11
Open Access | Times Cited: 3
Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Junning Liu, Linfeng Yang, Wei Song, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 17, pp. 16191-16201
Closed Access | Times Cited: 9
Junning Liu, Linfeng Yang, Wei Song, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 17, pp. 16191-16201
Closed Access | Times Cited: 9
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology Research (2023) Vol. 54, Iss. 4, pp. 382-391
Closed Access | Times Cited: 9
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology Research (2023) Vol. 54, Iss. 4, pp. 382-391
Closed Access | Times Cited: 9
Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
Sihao Du, Ke Cao, Zhenshun Wang, et al.
Medicine (2023) Vol. 102, Iss. 23, pp. e33852-e33852
Open Access | Times Cited: 8
Sihao Du, Ke Cao, Zhenshun Wang, et al.
Medicine (2023) Vol. 102, Iss. 23, pp. e33852-e33852
Open Access | Times Cited: 8
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
Bi‐Cheng Wang, Bo‐Hua Kuang, Guo‐He Lin
Targeted Oncology (2024) Vol. 19, Iss. 2, pp. 203-212
Closed Access | Times Cited: 3
Bi‐Cheng Wang, Bo‐Hua Kuang, Guo‐He Lin
Targeted Oncology (2024) Vol. 19, Iss. 2, pp. 203-212
Closed Access | Times Cited: 3
Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
Saixin Li, Zeyu Zhang, Zheng Wang, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 2
Saixin Li, Zeyu Zhang, Zheng Wang, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 2
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
Ryosuke Tsunemitsu, Motoyasu Tabuchi, Shinya Sakamoto, et al.
Surgical Case Reports (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Ryosuke Tsunemitsu, Motoyasu Tabuchi, Shinya Sakamoto, et al.
Surgical Case Reports (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13715-13715
Open Access | Times Cited: 6
Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13715-13715
Open Access | Times Cited: 6
Robot-assisted extended rectal anterior resection for peritoneal dissemination of hepatocellular carcinoma invading rectum after atezolizumab plus bevacizumab combined therapy
Wataru Hirata, Yoshiro Itatani, Koya Hida, et al.
International Cancer Conference Journal (2024) Vol. 13, Iss. 4, pp. 336-341
Closed Access | Times Cited: 1
Wataru Hirata, Yoshiro Itatani, Koya Hida, et al.
International Cancer Conference Journal (2024) Vol. 13, Iss. 4, pp. 336-341
Closed Access | Times Cited: 1
Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors
Yoh Asahi, Tatsuhiko Kakisaka, Toshiya Kamiyama, et al.
Hepatology Research (2024)
Closed Access | Times Cited: 1
Yoh Asahi, Tatsuhiko Kakisaka, Toshiya Kamiyama, et al.
Hepatology Research (2024)
Closed Access | Times Cited: 1
Successful radical surgery for lymph node metastasis in a patient with hepatocellular carcinoma following atezolizumab plus bevacizumab combination therapy: a case report and literature review
Ken Sato, Takehiro Shimizu, Akira Watanabe, et al.
Clinical Journal of Gastroenterology (2024) Vol. 17, Iss. 6, pp. 1067-1074
Closed Access | Times Cited: 1
Ken Sato, Takehiro Shimizu, Akira Watanabe, et al.
Clinical Journal of Gastroenterology (2024) Vol. 17, Iss. 6, pp. 1067-1074
Closed Access | Times Cited: 1
Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies
Claudia Campani, D C Pallas, Sabrina Sidali, et al.
JHEP Reports (2024) Vol. 6, Iss. 11, pp. 101190-101190
Open Access | Times Cited: 1
Claudia Campani, D C Pallas, Sabrina Sidali, et al.
JHEP Reports (2024) Vol. 6, Iss. 11, pp. 101190-101190
Open Access | Times Cited: 1
First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison
Robert Mahn, Oscar André Glüer, Farsaneh Sadeghlar, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 81-94
Open Access | Times Cited: 1
Robert Mahn, Oscar André Glüer, Farsaneh Sadeghlar, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 81-94
Open Access | Times Cited: 1
Differential liver function at cessation of atezolizumab-bevacizumab versus lenvatinib in HCC: a multicenter, propensity-score matched comparative study
Ji Won Han, Pil Soo Sung, Jae-Sung Yoo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Ji Won Han, Pil Soo Sung, Jae-Sung Yoo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
Mah I Kan Changez, Maimoona Khan, Muhammad Uzair, et al.
Journal of Gastrointestinal Cancer (2023) Vol. 55, Iss. 1, pp. 467-481
Closed Access | Times Cited: 3
Mah I Kan Changez, Maimoona Khan, Muhammad Uzair, et al.
Journal of Gastrointestinal Cancer (2023) Vol. 55, Iss. 1, pp. 467-481
Closed Access | Times Cited: 3
Sequencing Systemic Therapy in Hepatocellular Carcinoma
Ben Ponvilawan, Marc Roth
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 11, pp. 1580-1597
Closed Access | Times Cited: 2
Ben Ponvilawan, Marc Roth
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 11, pp. 1580-1597
Closed Access | Times Cited: 2
